The global dry eye syndrome treatment market is estimated to be valued at over US$ 4.2 Bn in 2020, and is expected to exhibit an impressive CAGR of 7% over the forecast period (2020-2030).
The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably, the late-stage pipeline has three products with novel mechanisms of action to treat the inflammation associated with the disease.
According to the latest research report by IMARC Group, The global dry eye syndrome market size reached USD 5.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.0 Billion by 2033, exhibiting a growth rate (CAGR) of 4.78% during 2025-2033. More Info:- https://www.imarcgroup.com/dry-eye-syndrome-market
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026.
According to the latest research report by IMARC Group, The Latin America dry eye syndrome market size reached US$ 263.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 419.0 Million by 2032, exhibiting a growth rate (CAGR) of 5.2% during 2024-2032. More Info:- https://www.imarcgroup.com/latin-america-dry-eye-syndrome-market
According to the latest research report by IMARC Group, The global dry eye syndrome market size reached US$ 4.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032. More Info:- https://www.imarcgroup.com/dry-eye-syndrome-market
The global dry eye medication market size will grow from $8.67 billion in 2022 to $9.62 billion in 2023 at a compound annual growth rate (CAGR) of 11.0%.
According to the latest research report by IMARC Group, The Japan dry eye syndrome market size reached US$ 134.7 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 173.5 Million by 2028, exhibiting a growth rate (CAGR) of 4.1% during 2023-2028. More Info:- https://www.imarcgroup.com/japan-dry-eye-syndrome-market
According to the latest research report by IMARC Group, The Europe dry eye syndrome market size reached US$ 757.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,153.5 Million by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032. More Info:- https://www.imarcgroup.com/europe-dry-eye-syndrome-market
The global Dry Eye Syndrome treatment market size was USD 4.29 Billion in 2022 and is expected to reach USD 6.21 Billion by 2032, and register a rapid revenue CAGR of 4.2% during the forecast period. Increasing geriatric population, technical developments in the industry, and rising awareness and adoption of treatment choices are major factors driving market revenue growth. Dry eye syndrome is becoming more common as a result of aging population, increasing use of Digital gadgets, and harmful effects of environmental conditions on eyes, among other factors.
According to the latest research report by IMARC Group, The Latin America dry eye syndrome market size reached US$ 248.4 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 356.3 Million by 2028, exhibiting a growth rate (CAGR) of 5.9% during 2023-2028. More Info:- https://www.imarcgroup.com/latin-america-dry-eye-syndrome-market
According to the latest research report by IMARC Group, The Europe dry eye syndrome market size reached US$ 719 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 986 Million by 2028, exhibiting a growth rate (CAGR) of 5.3% during 2023-2028. More Info:- https://www.imarcgroup.com/europe-dry-eye-syndrome-market
According to the latest research report by IMARC Group, The global dry eye syndrome market size reached US$ 4.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 6.3 Billion by 2028, exhibiting a growth rate (CAGR) of 5.67% during 2023-2028. More Info:- https://www.imarcgroup.com/dry-eye-syndrome-market
Dry Eye Syndrome Treatment Market: APEJ Region to Lead in Terms of CAGR During the Forecast Period: Global Industry Analysis 2012-2016 and Opportunity Assessment 2017-2027
According to the latest research report by IMARC Group, the Latin America dry eye syndrome market is expected to exhibit a CAGR of X% during 2022-2027. More info:- https://www.imarcgroup.com/latin-america-dry-eye-syndrome-market
The dry eye syndrome treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with the CAGR of 8.72% in the forecast period of 2021 to 2028.
DecisionDatabases.com, a market research firm adds a report Global Dry Eye Syndrome Drugs Market Research Report 2021 to its repository. The report gives a detailed account of the industry - Sales, Revenue Size, Share, Exports, Imports, and Production Volume etc.
The global dry eye syndrome treatment market is estimated to be valued at over US$ 4.2 Bn in 2020, and is expected to exhibit an impressive CAGR of 7% over the forecast period (2020-2030).
GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022”. Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation.
Dry eye syndrome is a condition which has an increasing prevalence along with the increasing ages. It is around 50.0% more common in the women as compared to men. Dry eye if left untreated can lead to ulcers, pain, scars on the cornea or some loss of the vision. However, the permanent loss of vision due to dry eye is uncommon.
The global dry eye syndrome treatment market is estimated to be valued at over US$ 4.2 Bn in 2020, and is expected to exhibit an impressive CAGR of 7% over the forecast period (2020-2030).
Dry eye syndrome is a condition which has an increasing prevalence along with the increasing ages. It is around 50.0% more common in the women as compared to men. Dry eye if left untreated can lead to ulcers, pain, scars on the cornea or some loss of the vision. However, the permanent loss of vision due to dry eye is uncommon.
The global dry eye syndrome treatment market is estimated to be valued at over US$ 4.2 Bn in 2020, and is expected to exhibit an impressive CAGR of 7% over the forecast period (2020-2030).
Dry eye syndrome is a condition which has an increasing prevalence along with the increasing ages. It is around 50.0% more common in the women as compared to men. Dry eye if left untreated can lead to ulcers, pain, scars on the cornea or some loss of the vision. However, the permanent loss of vision due to dry eye is uncommon.
The global dry eye syndrome treatment market is estimated to be valued at over US$ 4.2 Bn in 2020, and is expected to exhibit an impressive CAGR of 7% over the forecast period (2020-2030).
Dry eye syndrome is a condition which has an increasing prevalence along with the increasing ages. It is around 50.0% more common in the women as compared to men. Dry eye if left untreated can lead to ulcers, pain, scars on the cornea or some loss of the vision. However, the permanent loss of vision due to dry eye is uncommon.
The global dry eye syndrome treatment market is estimated to be valued at nearly US$ 3,560 Mn by 2017 end, and is projected to reach about US$ 6,610 Mn by the end of 2027, registering a CAGR of 6.4% over the forecast period.
The dry eye disease (DED) prevalence was 5.28% overall, with 2.96% male beneficiaries and 7.78% female beneficiaries. Get more insights about our latest blog.
The global dry eye disease market capturing a revenue share of $8884.34 million by 2032, CAGR of 5.11% during the assessment forecast period, 2023-2032. Read More
According to Coherent Market Insights, Eye Health Supplements Market is expected to propel growth at US$ 43,205.8 Mn in 2020 and is expected to exhibit a CAGR of 12.7% between 2020-2027.
The global dry eye disease market capturing a revenue share of $8884.34 million by 2032, CAGR of 5.11% during the assessment forecast period, 2023-2032. Read More
A recent report published by TheBusinessResearchCompany on Dry Eye Medication Market provides in-depth analysis of segments and sub-segments in the global as well as regional. http://bit.ly/2k7doXa
The global dry eye medication market is expected to grow from $3.25 billion in 2020 to $3.72 billion in 2021 at a compound annual growth rate (CAGR) of 14.5%.
A recent report published by The Business Research Company on Dry Eye Medication Market provides in-depth analysis of segments and sub-segments in the global as well as regional.
A recent report published by TheBusinessResearchCompany on Dry Eye Medication Market provides in-depth analysis of segments and sub-segments in the global as well as regional. http://bit.ly/2k7doXa
The global eyelid surgery blepharoplasty market is expected to garner $7132.97 million by 2032, projecting a CAGR of 6.90% during 2024-2032. Get more insights
‘Sicca Syndrome (Sjogren) - Pipeline Review, H1 2016’, provides an overview of the Sicca Syndrome (Sjogren) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. Read More At: http://www.researchbeam.com/sicca-syndrome-sjogren-pipeline-review-h1-2016-market
The eye health supplements market was valued at US$ 1,572.33 million in 2019 and is projected to reach US$ 2,382.96 million by 2027; it is expected to grow at a CAGR of 5.5% from 2020 to 2027.
According to the latest research report by IMARC Group, The global eye health supplements market size is projected to exhibit a growth rate (CAGR) of 5.4% during 2024-2032. More Info:- https://www.imarcgroup.com/eye-health-supplements-market
According to the latest research report by IMARC Group, The global eye health supplements market is expected to exhibit a growth rate (CAGR) of 6% during 2023-2028. More Info:- https://www.imarcgroup.com/eye-health-supplements-market
Global eye health supplements market size is expected at $2.72 Bn by 2027 at a growth rate of 7.6% and share analysis by The Business Research Company.
The report Ophthalmology Therapeutics in Major Developed Markets to 2019 provides insights into two therapeutic indications in ophthalmology in Top Eight Markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications. For More Details: http://www.researchonglobalmarkets.com/ophthalmology-therapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-to-trigger-shift-in-treatment-paradigm-to-combination-therapies.html
Global photophobia drug market is rising gradually with a substantial CAGR in the forecast period of 2019-2026. Growing population of photophobia worldwide and emergence of drugs used in the treatment of risk associated with photophobia condition such as migraine and dry eyes are the key factors to drive the market growth.
Global photophobia drug market is rising gradually with a substantial CAGR in the forecast period of 2019-2026. Growing population of photophobia worldwide and emergence of drugs used in the treatment of risk associated with photophobia condition such as migraine and dry eyes are the key factors to drive the market growth.